Most life-years saved were among people aged 60 years or older; estimates are more conservative than those that focused on the first year of vaccination ...

HealthDay News Cannabis use disorder (CUD) is associated with an increased risk for oral cancer, according to a study published in the September issue of Preventive Medicine Reports.

The gender pay gap for US physicians hit 26% in 2024, which was an increase from the 23% pay gap observed in 2023, according to Doximity’s Physician Compensation Report 2025.

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for lisocabtagene maraleucel (liso-cel) for adults with relapsed or ...

“We saw that critical-care management of brain swelling, along with immune modulating therapies such as plasma exchange and intravenous immunoglobin, appeared helpful for patients who recovered,” ...

In 2013, the Obama administration replaced the test with the Presidential Youth Fitness Program, which focused less on athletic skill and more on individual health.

Popular freeze-dried fruit snacks sold at Sam’s Club are being recalled because of possible listeria contamination.

The FDA is expected to decide on treatments for acromegaly, edema, HSCT-associated thrombotic microangiopathy, multiple sclerosis, and spinal muscular atrophy.

CMTX-101 is an investigational immune-enabling antibody designed to target and destroy the pro-inflammatory structure of bacteria biofilms.

The randomized, double-blind, placebo-controlled MODEL trial (ClinicalTrials.gov Identifier: NCT05516992) evaluated the safety and efficacy of SB-01 in 417 adults with CLBP and related disability due ...

David Holtzman, a retired privacy expert, said much of the technology already exists and that past federal efforts to set up similar systems “have proven to be ineffective." ...

The Food and Drug Administration (FDA) has issued another Complete Response Letter (CRL) to Regeneron (CRL) for the Biologics License Application (BLA) for odronextamab in relapsed/refractory ...